Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors

Class of 2007 Abstract === Objectives: To explore the effects of human immunodeficiency virus protease inhibitors (HPI) on insulin metabolism and protein degradation in HepG2 hepatocytes in vitro. Methods: To see if HIV-protease inhibitors affect insulin degradation in a dose-dependent manner, HepG...

Full description

Bibliographic Details
Main Author: Tsui, Brian
Other Authors: Vaillancourt, Richard
Language:en_US
Published: The University of Arizona. 2007
Subjects:
HIV
Online Access:http://hdl.handle.net/10150/624329
http://arizona.openrepository.com/arizona/handle/10150/624329
id ndltd-arizona.edu-oai-arizona.openrepository.com-10150-624329
record_format oai_dc
spelling ndltd-arizona.edu-oai-arizona.openrepository.com-10150-6243292017-06-23T03:00:30Z Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors Tsui, Brian Vaillancourt, Richard Fawcett, Janet Duckworth, William College of Pharmacy, The University of Arizona HIV HIV-Protease Inhibitors Insulin Metabolism Protein Degradation Class of 2007 Abstract Objectives: To explore the effects of human immunodeficiency virus protease inhibitors (HPI) on insulin metabolism and protein degradation in HepG2 hepatocytes in vitro. Methods: To see if HIV-protease inhibitors affect insulin degradation in a dose-dependent manner, HepG2 cells were incubated with various concentrations of tipranavir, indinavir, or atazanavir. After 125I-insulin was added, its degradation was measured by precipitation with trichloroacetic acid (TCA). To see the effect of HPIs on protein degradation, HepG2 cells labeled overnight with 3H-leucine were incubated with 50 mM of an HPI, followed by another HPI incubation including concentrations of insulin ranging from 10-12 to 10-6 M. Cells were solubilized and proteins were precipitated using TCA. Degradation was quantified as percent TCA soluble, normalized, plotted, and then compared using student’s t-test or one- way ANOVA. Results: Cellular insulin degradation was inhibited only by tipranavir at the highest concentrations of 75 and 100 mM (12.06 ± 1.07%, p=0.047 and 9.35 ± 0.44%, p=0.024, respectively) when compared to the control (17.01 ± 1.37%; n=3). None of the concentrations of indinavir or atazanavir decreased insulin degradation significantly. From the protein degradation experiments, the log EC50 of the control (no HPI) insulin dose-response curve was not statistically different compared to those of the individual HPIs. Conclusions: Except for high concentrations of tipranavir, it appears that HPI does not inhibit the cellular degradation of insulin. HPIs do not appear to inhibit the role of insulin in the inhibition of protein degradation significantly. 2007 text Electronic Report http://hdl.handle.net/10150/624329 http://arizona.openrepository.com/arizona/handle/10150/624329 en_US Copyright © is held by the author. The University of Arizona.
collection NDLTD
language en_US
sources NDLTD
topic HIV
HIV-Protease Inhibitors
Insulin Metabolism
Protein Degradation
spellingShingle HIV
HIV-Protease Inhibitors
Insulin Metabolism
Protein Degradation
Tsui, Brian
Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors
description Class of 2007 Abstract === Objectives: To explore the effects of human immunodeficiency virus protease inhibitors (HPI) on insulin metabolism and protein degradation in HepG2 hepatocytes in vitro. Methods: To see if HIV-protease inhibitors affect insulin degradation in a dose-dependent manner, HepG2 cells were incubated with various concentrations of tipranavir, indinavir, or atazanavir. After 125I-insulin was added, its degradation was measured by precipitation with trichloroacetic acid (TCA). To see the effect of HPIs on protein degradation, HepG2 cells labeled overnight with 3H-leucine were incubated with 50 mM of an HPI, followed by another HPI incubation including concentrations of insulin ranging from 10-12 to 10-6 M. Cells were solubilized and proteins were precipitated using TCA. Degradation was quantified as percent TCA soluble, normalized, plotted, and then compared using student’s t-test or one- way ANOVA. Results: Cellular insulin degradation was inhibited only by tipranavir at the highest concentrations of 75 and 100 mM (12.06 ± 1.07%, p=0.047 and 9.35 ± 0.44%, p=0.024, respectively) when compared to the control (17.01 ± 1.37%; n=3). None of the concentrations of indinavir or atazanavir decreased insulin degradation significantly. From the protein degradation experiments, the log EC50 of the control (no HPI) insulin dose-response curve was not statistically different compared to those of the individual HPIs. Conclusions: Except for high concentrations of tipranavir, it appears that HPI does not inhibit the cellular degradation of insulin. HPIs do not appear to inhibit the role of insulin in the inhibition of protein degradation significantly.
author2 Vaillancourt, Richard
author_facet Vaillancourt, Richard
Tsui, Brian
author Tsui, Brian
author_sort Tsui, Brian
title Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors
title_short Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors
title_full Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors
title_fullStr Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors
title_full_unstemmed Insulin Metabolism and Protein Degradation by HEPG2 Hepatocytes Treated with HIV-Protease Inhibitors
title_sort insulin metabolism and protein degradation by hepg2 hepatocytes treated with hiv-protease inhibitors
publisher The University of Arizona.
publishDate 2007
url http://hdl.handle.net/10150/624329
http://arizona.openrepository.com/arizona/handle/10150/624329
work_keys_str_mv AT tsuibrian insulinmetabolismandproteindegradationbyhepg2hepatocytestreatedwithhivproteaseinhibitors
_version_ 1718462114043002880